The Melanoma market will be impacted by adjuvant, advanced / metastatic and brain mets data presented during the European Society for Medical Oncology (ESMO) meeting in Barcelona, Spain.

Breaking Data will be working with 30 oncologists during the meeting to better understand the commercial implications of data presented for TECENTRIQ® (atezolizumab), COTELLIC® (cobimetinib), YERVOY® (ipilimumab), OPDIVO® (nivolumab), KEYTRUDA® (pembrolizumab), TAFINLAR® (dabrafenib) + MEKINIST® (trametinib), and IMLYGIC® (talimogene laherparepvec).

Trials covered include: CheckMate 067, CheckMate 238, IMspire170, IMMUNED, TRIDeNT.

Companies presenting data include: Amgen, Bristol-Myers Squibb, Genentech, Merck, Novartis.

Get immediate access to this 60-slide report so you can make better decisions today and prepare for tomorrow.

Melanoma Report ESMO 2019

European Society for Medical Oncology

Barcelona, Spain
Sep 27 to Oct 1

Share: